Rothschild Investment LLC’s Verve Therapeutics VERV Stock Holding History

Rothschild Investment LLC’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-285	Closed	-$3.2K	–	3252
2025 Q2	$3.2K	Buy	285 +5	+2%	+$29	﹤0.01%	1750
2025 Q1	$1.28K	Buy	280 +75	+37%	+$502	﹤0.01%	2194
2024 Q4	$1.16K	Buy	205 +40	+24%	+$226	﹤0.01%	2127
2024 Q3	$799	Buy	165 +145	+725%	+$842	﹤0.01%	2310
2024 Q2	$98	Buy	20 +10	+100%	+$63	﹤0.01%	2745
2024 Q1	$133	Buy	+10	New	+$133	﹤0.01%	2007

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Rothschild Investment LLC's VERV Position: Q3 2025 in Review

Rothschild Investment LLC sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 285 shares — an estimated $3.2K sold.

Rothschild Investment LLC first reported a position in VERV in Q1 2024 and held it in 6 quarters. The position peaked at $3.2K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

Rothschild Investment LLC reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
Rothschild Investment LLC sold 285 Verve Therapeutics shares in Q3 2025, an estimated $3.2K.
Rothschild Investment LLC first reported a position in Verve Therapeutics in Q1 2024 and held it in 6 quarters.
Rothschild Investment LLC's Verve Therapeutics position peaked at $3.2K in Q2 2025.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Rothschild Investment LLC's 13F filing for Q3 2025, filed 7 Nov 2025.